The NICE guideline on early and locally advanced breast cancer, (published in February 2009) updates the recommendations contained in this appraisal.
Paclitaxel is not recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.
Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any significant cost implications. Therefore, no costing template has been developed for this appraisal.
Update to guidance
NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.